AG
DNLI icon

Aperio Group’s Denali Therapeutics DNLI Stock Holding History

Aperio Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.58M Buy
18,851
+2,926
+18% +$177K ﹤0.01% 1347
2020
Q3 		$571K Buy
15,925
+5,772
+57% +$174K ﹤0.01% 1743
2020
Q2 		$245K Buy
+10,153
New +$239K ﹤0.01% 2103
2019
Q3 		– Sell
-667
Closed -$14K – 2434
2019
Q2 		$14K Buy
+667
New +$14.9K ﹤0.01% 2739

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's DNLI Position: Q4 2020 in Review

Aperio Group increased its Denali Therapeutics (DNLI) stake by 18% in Q4 2020, buying an estimated $177K and bringing the position to 18,851 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1347.

Aperio Group first reported a position in DNLI in Q2 2019 and has held it in 4 quarters since. 205 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

  • Aperio Group held 18,851 shares of Denali Therapeutics worth $1.58M as of Q4 2020.
  • Aperio Group bought 2,926 Denali Therapeutics shares in Q4 2020, an estimated $177K.
  • Denali Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1347 holding.
  • Aperio Group first reported a position in Denali Therapeutics in Q2 2019 and has held it in 4 quarters since.
  • 205 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.